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Introduction {#cdr12128-sec-0001}
============

In the United States, HF has become the most common discharge diagnosis in patients over 65 years of age [1](#cdr12128-bib-0001){ref-type="ref"}, [2](#cdr12128-bib-0002){ref-type="ref"}. Treatments remain inadequate and heart transplant options are severely limited. Therefore, pharmacotherapies designed to coincide with standard means of care are needed to prevent cardiac remodeling and attenuate the extensive cardiac injury and dysfunction associated with late‐stage heart failure (HF). Our laboratory and others have shown that subjects with congestive heart failure (CHF) have a deficit in circulating hydrogen sulfide (H~2~S) levels, and that sulfide levels are inversely correlated with severity of CHF [3](#cdr12128-bib-0003){ref-type="ref"}, [4](#cdr12128-bib-0004){ref-type="ref"}, [5](#cdr12128-bib-0005){ref-type="ref"}.

In mammals, hydrogen sulfide is enzymatically generated by cystathionine β‐synthase (CBS), cystathionine γ‐lyase (CSE) or 3‐mercaptopyruvate sulfur‐transferase (3‐MST) [6](#cdr12128-bib-0006){ref-type="ref"}. H~2~S and its metabolites are found throughout the body, including the heart, liver, kidney, brain, nervous system, lung, airway tissues, gastrointestinal tract, reproductive organs, skeletal muscle, pancreas, synovial joints, connective tissue, cochlea, and adipose tissues [7](#cdr12128-bib-0007){ref-type="ref"}. Dysfunction of CSE, resulting in impaired H~2~S generation, has been cited as a significant contributor to pathology in numerous disease states [8](#cdr12128-bib-0008){ref-type="ref"}, [9](#cdr12128-bib-0009){ref-type="ref"}, [10](#cdr12128-bib-0010){ref-type="ref"}. Furthermore, H~2~S plays an important role in the normal physiology of the cardiovascular system with important actions on both the heart and the circulation [6](#cdr12128-bib-0006){ref-type="ref"}, [11](#cdr12128-bib-0011){ref-type="ref"}. In preclinical models, H~2~S therapy decreases disease severity by numerous mechanisms, including antioxidant activity, promoting angiogenesis, modulating mitochondrial function, reducing inflammation, upregulating antioxidant gene programs, inhibiting cell death, and attenuating fibrosis [6](#cdr12128-bib-0006){ref-type="ref"}, [12](#cdr12128-bib-0012){ref-type="ref"}, [13](#cdr12128-bib-0013){ref-type="ref"}, [14](#cdr12128-bib-0014){ref-type="ref"}.

A second endogenous gaseous messenger, nitric oxide (NO), is produced throughout the body and is critical for cardiovascular homeostasis [15](#cdr12128-bib-0015){ref-type="ref"}, [16](#cdr12128-bib-0016){ref-type="ref"}. Our laboratory and others have previously shown that NO is highly cytoprotective and that maintaining NO bioavailability protects against the development and progression of HF [3](#cdr12128-bib-0003){ref-type="ref"}, [17](#cdr12128-bib-0017){ref-type="ref"}, [18](#cdr12128-bib-0018){ref-type="ref"}. Similarly to H~2~S, NO levels are diminished in HF patients compared with healthy controls [3](#cdr12128-bib-0003){ref-type="ref"}. Recently, H~2~S has been shown to elevate circulating levels of NO by increasing the activity of endothelial nitric oxide synthase (eNOS) [9](#cdr12128-bib-0009){ref-type="ref"}, [12](#cdr12128-bib-0012){ref-type="ref"}. In addition, a genetic deficiency of CSE resulting in H~2~S deficit is associated with eNOS dysfunction and perturbed downstream NO‐dependent signaling, but is corrected with administration of an H~2~S donor [9](#cdr12128-bib-0009){ref-type="ref"}.

In preclinical studies, the novel long‐acting H~2~S prodrug, SG1002, attenuates left ventricular (LV) remodeling and dysfunction in a pressure‐overload model of HF [12](#cdr12128-bib-0012){ref-type="ref"}. Administration of SG1002 significantly increased both H~2~S and NO levels and decreased numerous indices of disease [12](#cdr12128-bib-0012){ref-type="ref"}. Given the dramatic cardioprotective actions of SG1002 in preclinical studies, here we examined the safety of this pluripotent compound in healthy and CHF patients in a placebo‐controlled dose‐escalation phase I clinical trial. The purpose of this trial was to evaluate initial safety and maximum tolerated oral doses of SG1002. SG1002 significantly augments circulating H~2~S and plasma nitrite levels in healthy subjects and HF patients. SG1002 was also well tolerated and safe at all doses tested.

Methods {#cdr12128-sec-0002}
=======

Inclusion/Exclusion Criteria for Healthy Subjects {#cdr12128-sec-0003}
-------------------------------------------------

*Inclusion:* Healthy male volunteers between 25 and 34 years of age with a body mass index (BMI) between 19 and 30 kg/m^2^, and no clinically significant findings in the medical history and physical examination; no clinically significant laboratory values and urinalysis; normal electrocardiogram (ECG), blood pressure and heart rate; willing to use contraception (single barrier methods); and willing and able to provide written consent. *Exclusion:* subjects could not meet any of the following exclusion criteria: have received blood products within 1 month prior to screening; have received any investigational research agent within 30 days or 5 half‐lives (whichever is longer) prior to the first dose of trial drug; have a history of thyroidectomy or thyroid disease that required medication within the past 12 months; have had serious angioedema episodes within the previous 3 years; have HIV, hepatitis B or C positive; have a history of or current clinically significant GI, hepatic, renal, cardiovascular, respiratory, endocrine, oncological, immunodeficiency, neurological, metabolic, hematological, or autoimmune disorder; have a history of or current tuberculosis, epilepsy, diabetes, or glaucoma; hypersensitivity to sulfur compounds, unable to provide repeated blood samples without undue trauma or distress; or anticipate surgery within the trial period.

Inclusion/Exclusion Criteria for Congestive Heart Failure Subjects {#cdr12128-sec-0004}
------------------------------------------------------------------

*Inclusion:* Aged between 40 and 71 years; have symptomatic HF, with New York Heart Association (NYHA) classification of II or III; ambulatory; left ventricular ejection fraction of less than 40%; normal hemoglobin screening; and CHF has been stable for the previous 3 months. *Exclusion:* subjects could not meet any of the following exclusion criteria: pregnant or breastfeeding; myocardial infarction, unstable angina, stroke, cerebrovascular accident, percutaneous coronary intervention, open heart surgery or transient ischemic attack within 3 months of screening; hypotension; poorly controlled hypertension; serious liver disease; life expectancy less than 6 months; evidence of drug or alcohol abuse; and HIV, or hepatitis B or C positive. SG1002‐treated HF subjects had the following comorbidities: type two diabetes (33.3%), dyslipidemia (50%), hypertension (33.3%), ischemic heart disease (16.7%), cardiomyopathy (66.7%), atrial fibrillation (16.7%), implantable defibrillator (100%), acute myocardial infarction (16.7%), obesity (50%). Placebo‐treated HF subjects had the following comorbidities: type two diabetes (50%), dyslipidemia (100%), hypertension (50%), nonischemic heart disease (50%), atrial fibrillation (50%), implantable defibrillator (100%), and acute myocardial infarction (50%).

Study Procedures {#cdr12128-sec-0005}
----------------

Eight healthy subjects were randomized 1:3 (placebo:active groups). One subject was dropped from the study following the first dose due to recreational drug use. The seven remaining subjects were randomly assigned to receive either placebo (n = 2) or SG1002 (n = 5). The study protocol is depicted in Figure [1](#cdr12128-fig-0001){ref-type="fig"}. Initially, subjects received 200 mg oral capsules SG1002 or placebo twice daily (BID) for 7 days (visit 1, days 0--6); then increased to 400 mg SG1002 or placebo BID for 7 days (visit 2, days 7--13); then increased to 800 mg SG1002 or placebo BID for 7 days (visit 3, days 14--21). In an identical dose‐escalation format, CHF patients (n = 8) received either placebo (n = 2) or SG1002 (n = 6). CHF patients received 200 mg oral capsules SG1002 or placebo BID for 7 days (visit 1, days 0--6); then increased to 400 mg SG1002 or placebo BID for 7 days (visit 2, days 7--13); then increased to 800 mg SG1002 or placebo BID for 7 days (visit 3, days 14--21).

![SG1002 phase I clinical trial in heart failure patients. Subjects received 200 mg oral capsules SG1002 or placebo twice daily (BID) for 7 days (visit 1, days 0--6); then increased to 400 mg SG1002 or placebo BID for 7 days (visit 2, days 7--13); then increased to 800 mg SG1002 or placebo BID for 7 days (visit 3, days 14--21). Blood was collected for pharmacokinetic analysis at 0, 0.5, 1, 2, and 4 h immediately following the administration of SG1002 or placebo at visits 1 and 2 and at 0, 0.5, 1, 2, 4, 6, 12, and 24 h during visit 3. Samples for the analysis of brain natriuretic peptide (BNP) and oxidative stress (glutathione) were taken on days 0, 7, 14, and 21 prior to the administration of SG1002. Parameters for safety, including physical examination, vital sign measurements, and electrocardiogram (ECG), were measured at baseline, 1, 2 and 3 weeks time points.](CDR-33-216-g001){#cdr12128-fig-0001}

Safety Assessment {#cdr12128-sec-0006}
-----------------

Parameters for safety of SG1002 included: physical examination, vital sign measurements, and electrocardiogram (ECG). Adverse event (AE) causality assessment was labeled: "definite" (\>95% likely the trial drug caused the event), "highly likely" (75--95%), "probably" (50--74%), "possible" (25--49%), "unlikely" (\<25%), and "unknown" if the case in not informative enough to assign the event to any of the above categories. AE severity classification was considered "mild" if there was an awareness of sign or symptom but easily tolerated and does not alter normal activity, "moderate" if the sign or symptom causes discomfort or interference with unusual activity, or "severe" if the sign or symptom causes significant impairment of function or incapacitation, or inability to perform normal activities.

Blood Sample Collection {#cdr12128-sec-0007}
-----------------------

Blood was collected for pharmacokinetic analysis at 0, 0.5, 1, 2, and 4 h immediately following the administration of SG1002 or placebo at visits 1 and 2 and at 0, 0.5, 1, 2, 4, 6, 12, and 24 h during visit 3. Samples for the analysis of brain natriuretic peptide (BNP) and oxidative stress (glutathione) were taken on days 0, 7, 14, and 21 prior to the administration of SG1002.

Measurement of Hydrogen Sulfide {#cdr12128-sec-0008}
-------------------------------

Plasma free H~2~S levels were measured using gas chromatography chemiluminescence (7890 Series GC, G660XA Series Chemiluminescence Detector; Agilent, Santa Clara, CA, USA). Free H~2~S in plasma was liberated by incubating in 1M sodium citrate solution at 37°C for 10 min. The resultant headspace gases were analyzed using the GC system. For the measurement of H~2~S released from sulfane sulfur, 0.1 mL of sample homogenate and 0.1 mL of 15 mM DTT in 0.1 mM Tris/HCl, pH 9.0, were placed in a in a small glass vial, sealed, and incubated at 37°C for 50 min. After the incubation, 0.4 mL of 1 M sodium citrate buffer was injected through the rubber stopper and the mixture was incubated at 37°C for 10 min with shaking at 125 rpm on a rotary shaker to facilitate the release of H~2~S gas from the aqueous phase. After shaking, head‐space gas was injected into a gas chromatograph for quantification.

Measurement of Plasma Nitrite (NO~2~ ^−^) {#cdr12128-sec-0009}
-----------------------------------------

Plasma nitrite concentrations were quantified by an automated ion chromatography system (ENO30 Analyzer; Eicom San Diego, CA, USA). Nitrite was separated by a column (NO‐PAK with polystyrene polymer; Eicom). The mobile phase, delivered at a pump rate of 0.33 mL/min, was 10% methanol containing 0.15 mol/L NaCl‐NH~4~Cl and 0.5 g/L of tetrasodium EDTA. The Griess reagent, which was 1.25% HCl containing 5 g/L sulfanilamide with 0.25 g/L *N*‐naphthylethylenediamine, was delivered at a rate of 0.1 mL/min.

Glutathione Measurements {#cdr12128-sec-0010}
------------------------

GSH and GSSG levels in patient red blood cells (RBCs) were determined using high‐performance liquid chromatography (HPLC). An equal volume of 10% TCA was added to the RBCs, and the samples were then vortexed and allowed to incubate overnight at 4°C. Following incubation, the samples were centrifuged at 10,000 rpm for 2 min at 4°C to pellet the precipitated proteins. The supernatant was removed and 80 mM iodoacetic acid (10% v/v) was added. The pH was adjusted to \~7.5--8 using 1 M potassium carbonate and allowed to incubate at room temperature for 1 h. Samples were then derivatized with 1‐fluoro‐2,4‐dinitrobenzene (DNFB), pH adjusted to 7 with 1M potassium carbonate and incubated at 4°C overnight in the dark. Samples were then centrifuged at 10,000 rpm at 4°C for 5 min and filtered through a 0.45‐micron syringe filter. Separation of GSH and GSSG derivatives was performed on a 250 mm × 4.6 mm Lichrosorb NH2 10 micron anion exchange column. GSH and GSSG were quantified by comparing standards derivatized in the same manner. RBC pellets were analyzed using Drabkin\'s assay to give final concentrations of GSH and GSSG in nmol/mg hemoglobin.

Statistical Analysis {#cdr12128-sec-0011}
--------------------

Data analysis was performed using Prism 6 software. Statistical significance was evaluated using a 1‐way ANOVA with a Bonferroni multiple comparison correction test. All statistical comparisons indicated are to baseline (pre‐treatment) values. A *P*‐value \<0.05 was considered statistically significant. All data are expressed as mean ± SEM unless otherwise noted. SEM = standard error of the mean, SD = standard deviation.

Results {#cdr12128-sec-0012}
=======

Demographics {#cdr12128-sec-0013}
------------

All normal subjects were men, between the ages of 25 and 34, with an average age of 27.5 years and an average BMI of 23.6 (Table [1](#cdr12128-tbl-0001){ref-type="table-wrap"}). One subject\'s (SG1002 treated group) participation in the study was terminated after visit 1 due to evidence of drug or alcohol abuse (Exclusion criteria \#15). All other subjects completed the trial. HF subjects were Caucasian, between the ages of 40 and 71, with an average age of 57.7 years and an average BMI of 31.3. Six of the eight subjects were men, with both women randomized to the SG1002 treatment group (Table [1](#cdr12128-tbl-0001){ref-type="table-wrap"}). Adherence was defined as taking at least 80% of the required study doses and was assessed at each visit. All healthy subjects and HF subjects adhered to investigational product usage throughout the study. Subject 05 (healthy subject) missed two capsules of placebo. Subject 09 (with HF) missed four capsules of placebo. Subject 11 (with CHF) missed three capsules of SG1002 (one 800 mg dose). All other subjects were 100% adherent to investigational product. Concomitant medications reported by healthy subjects included ascorbic acid, fish oil, ibuprofen, paracetamol and codeine. Concomitant medications reported by subjects with HF are listed in Table [2](#cdr12128-tbl-0002){ref-type="table-wrap"}.

###### 

Participant demographics

  Demographic               Healthy subjects   Heart failure subjects                 
  ------------------------- ------------------ ------------------------ ------------- -------------
  Age, years, mean (SD)     27.0 (0.0)         27.7 (3.4)               56.0 (12.7)   58.2 (14.2)
  Sex, n (%)                                                                          
  Male                      2                  6                        2             4
  Female                    0                  0                        0             2
  Race                                                                                
  Caucasian                 2                  5                        2             6
  South Asian               0                  1                                      
  Height, cm, mean (SD)     179.0 (7.1)        177.7 (3.8)              171.5 (6.4)   172.5 (7.3)
  Weight, kg, mean (SD)     73.0 (7.1)         75.5 (5.7)               99.0 (25.5)   90.2 (22.2)
  BMI, kg/m^2^, mean (SD)   22.8 (0.4)         23.9 (1.9)               33.4 (6.2)    30.6 (8.6)

John Wiley & Sons, Ltd

###### 

Concomitant medication use (Heart failure subjects)

  Subject \#   Concomitant medication (preferred name)                                                                                                                                                                                                                                                                                         Treatment
  ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  9            Panadeine co, fenofibrate, omeprazole, folic acid, metformin, clopidogrel bisulfate, mirtazapine, allopurinol, hydrochlorothiazide, potassium chloride, furosemide, spironolactone, carvedilol, methyldopa, warfarin, amlodipine besilate, amino acids with hydroxocobalamin, rosuvastatin, ramipril, hydralazine, ivabradine   Placebo
  10           Acetylsalicylic acid, furosemide, simvastatin, gliclazide, isosorbide mononitrate, enalapril maleate, bisoprolol fumarate, warfarin, digoxin, potassium chloride, paracetamol, bumetanide, escitalopram oxalate                                                                                                                 SG1002
  11           Warfarin, spironolactone, amiodarone, gemfibrozil, perindopril erbumine, carvedilol, tiotropium bromide, budesonide with formoterol fumarate                                                                                                                                                                                    SG1002
  12           Salbutamol, spironolactone, pantoprazole, fluticasone propionate with salmeterol, desvenlafaxine, panadeine co, acetylsalicyclic acid, insulin aspart, fosinopril sodium, insulin glargine, furosemide, trimethoprim, rosuvastatin, colchicine, potassium chloride, allopurinol, vitamin D,                                     SG1002
  13           Carvedilol, spironolactone, levothyroxine sodium, vitamin B, perindopril, ivabradine hydrochloride                                                                                                                                                                                                                              SG1002
  14           Glucosamine, acetylsalicylic acid, magnesium sulfate, fish oil, furosemide, ascorbic acid, metoprolol tartrate, spironolactone, rosuvastatin calcium, perindopril erbumine, ubidecarenone                                                                                                                                       SG1002
  15           Oxazepam, perindopril erbumine, spironolactone, furosemide, bisoprolol fumarate                                                                                                                                                                                                                                                 SG1002
  16           Panadeine co, metformin, acetylsalicylic acid, esomeprazole sodium, bisoprolol, perindopril, rosuvastatin                                                                                                                                                                                                                       Placebo
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Safety Data {#cdr12128-sec-0014}
-----------

There were a total of 10 AEs recorded during the study of healthy subjects (Table [3](#cdr12128-tbl-0003){ref-type="table-wrap"}). All events resolved and no changes in study product dosing were required. There were a total of three AEs recorded during the study of subjects with HF, including two AEs that occurred prior to the first dose of investigational product. The pretreatment adverse events were moderate hyperkalemia (resolved) and mild upper respiratory tract infection (ongoing). The treatment emergent adverse event, mild bruising at the site of blood draw, occurred after the administration of the 200 mg dose and was considered unrelated. Mild gastrointestinal (GI) issues such as flatulence and nausea were observed in SG1002‐treated patients. However, the vast majority of preclinical studies show that H~2~S is GI protective. For example, H~2~S has been reported to enhance ulcer healing, reduce inflammation, and promotes colitis healing [19](#cdr12128-bib-0019){ref-type="ref"}, [20](#cdr12128-bib-0020){ref-type="ref"}, [21](#cdr12128-bib-0021){ref-type="ref"}, [22](#cdr12128-bib-0022){ref-type="ref"}. Additionally, all GI incidences were categorized as "mild" and not all were definitely caused by SG1002.

###### 

Treatment emergent adverse events (Healthy subjects)

  Adverse events                       Placebo    SG1002     Dose         Severity[a](#cdr12128-note-0005){ref-type="fn"}   Causality[b](#cdr12128-note-0006){ref-type="fn"}
  ------------------------------------ ---------- ---------- ------------ ------------------------------------------------- --------------------------------------------------
  Total AEs, n                         4          6                                                                         
  Subjects with ≥1 AE, n (%)           2 (100)    3 (50.0)                                                                  
  Gastrointestinal disorders, n (%)               3 (50.0)                                                                  
  Diarrhea                                        1 (16.7)   200 mg       Mild                                              Possible
  Flatulence                                      1 (16.7)   800 mg       Mild                                              Probable
  Nausea                                          1 (16.7)   800 mg       Mild                                              Definite
  Vomiting                                        1 (16.7)   800 mg       Mild                                              Definite
  Infections and infestations, n (%)   2 (100)                                                                              
  URTI                                 2 (100)               800 mg pbo   Mild                                              Unlikely
  200 mg pbo                           Moderate   Unlikely                                                                  
  Nervous system disorders, n (%)      1 (50.0)   1 (16.7)                                                                  
  Headache                             1 (50.0)              400 mg pbo   Moderate                                          Possible
  Lethargy                                        1 (16.7)   200 mg       Mild                                              Unlikely
  Syncope                                         1 (16.7)   200 mg       Mild                                              Unlikely
  Psychiatric disorders, n (%)         1 (50.0)                                                                             
  Libido increased                     1 (50.0)              400 mg pbo   Mild                                              Possible

Pbo: placebo.

bid: twice daily.

URTI: upper respiratory tract infection.

Severity as assessed by the investigator.

Causality is the investigator assessment of the likelihood that the investigational product caused the adverse event.

John Wiley & Sons, Ltd

There were no notable changes in clinical chemistry test results in healthy subjects or subjects with HF (Table [4](#cdr12128-tbl-0004){ref-type="table-wrap"}) nor were there notable changes in vital signs, including blood pressure or pulse (Table [5](#cdr12128-tbl-0005){ref-type="table-wrap"}). The ECG results for healthy subjects were all reported as normal, and for subjects with HF, there were no new clinically significant abnormalities detected.

###### 

Liver and renal chemistry data in healthy and heart failure subjects following 200 mg (Visit 1), 400 mg (Visit 2), and 800 mg (Visit 3) SG1002

                        ALT (U/L)     AST (U/L)    Creatinine (umol/L)   Urea (mmol/L)                                                                                                                                                       
  --------------------- ------------- ------------ --------------------- --------------- ------------ ------------ ------------ ------------- ------------- ------------- ------------- ------------- ------------ ------------ ------------ ------------
  Healthy                                                                                                                                                                                                                                    
  SG1002, Mean (SEM)    22.8 (5.1)    20.2 (6.1)   18.6 (3.9)            17.8 (3.2)      20.2 (3.0)   17.6 (3.3)   20.4 (2.9)   17.2 (2.1)    78.2 (3.7)    73.4 (3.6)    74.6 (3.6)    78.2 (4.3)    4.56 (0.7)   4.3 (0.4)    4.92 (0.7)   5.24 (0.6)
  Placebo, Mean (SEM)   17 (2.0)      15.5 (0.5)   21 (4.0)              18 (3.0)        22 (4.0)     19.5 (1.5)   34 (8.0)     27.5 (4.5)    77.5 (9.5)    73 (11.0)     84 (11.0)     78.5 (11.5)   3.75 (0.8)   4.6 (0.2)    5.75 (0.5)   4.7 (1.0)
  CHF                                                                                                                                                                                                                                        
  SG1002, Mean (SEM)    40.3 (21.9)   35 (17.4)    29.2 (10.8)           37.7 (20.5)     31 (10.1)    30 (11.7)    28.5 (9.2)   35.8 (16.3)   94.5 (19.7)   88.2 (14.4)   86.7 (15.8)   88.3 (11.5)   7.9 (1.6)    7.6 (1.2)    8.5 (1.6)    8.4 (1.3)
  Placebo, Mean (SEM)   37.5 (11.5)   25 (5.0)     21 (1.0)              29.5 (8.5)      26.5 (9.5)   22 (3.0)     19.5 (0.5)   25 (5.0)      78 (2.0)      72.5 (2.5)    69.5 (0.5)    83.5 (5.5)    6.65 (0.2)   6.15 (0.9)   4.6 (0.1)    5.45 (0.3)
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###### 

Heart rate and blood pressure data from healthy and HF subjects

                                    Day 0         Day 7          Day 14        Day 21
  --------------------------------- ------------- -------------- ------------- --------------
  Pulse rate (beats per minute)                                                
  Placebo (Healthy)                 44.0 (1.4)    56.5 (10.6)    57.0 (5.7)    54.0 (2.8)
  SG1002 (Healthy)                  63.2 (12.3)   62.8 (8.7)     62.2 (9.0)    59.7 (11.7)
  Placebo (HF)                      75.0 (22.6)   75.0 (5.7)     76.5 (2.1)    80.0 (26.9)
  SG1002 (HF)                       75.2 (8.6)    68.0 (5.9)     72.0 5.9)     73.2 (8.4)
  Systolic blood pressure (mmHg)                                               
  Placebo (Healthy)                 116.5 (0.7)   125.5 (4.9)    119.0 (0.0)   119.0 (5.7)
  SG1002 (Healthy)                  123.0 (3.8)   116.8 (4.8)    121.2 (3.5)   122.3 (12.9)
  Placebo (HF)                      116.5 (0.7)   118.5 (0.7)    116.5 (1.4)   130.0 (0.0)
  SG1002 (HF)                       114.0 (8.8)   111.7 (16.4)   108.5 (5.3)   112.2 (8.8)
  Diastolic blood pressure (mmHg)                                              
  Placebo (Healthy)                 63.0 (11.3)   79.5 (0.7)     77.5 (2.1)    72.5 (2.1)
  SG1002 (Healthy)                  75.8 (5.9)    69.8 (5.9)     78.2 (6.3)    75.5 (7.7)
  Placebo (HF)                      76.0 (12.8)   78.5 (0.7)     81.5 (8.5)    90.5 (9.2)
  SG1002 (HF)                       68.0 (10.5)   73.3 (16.7)    67.5 (7.4)    70.3 (6.3)

John Wiley & Sons, Ltd

SG1002 Elevated H~2~S Levels in Healthy and Heart Failure Subjects {#cdr12128-sec-0015}
------------------------------------------------------------------

Compared to baseline (pretreatment values), peak free‐H~2~S levels from each patient (between 0.5 and 4 h following SG1002 treatment) were increased at the 400 mg (*P* \< 0.01) and 800 mg (*P* \< 0.01) doses in healthy subjects (Figure [2](#cdr12128-fig-0002){ref-type="fig"}A). In HF subjects, a significant increase in free‐H~2~S was observed following the 400 mg dose (*P* \< 0.05), compared to baseline values (Figure [2](#cdr12128-fig-0002){ref-type="fig"}B). No significant elevations in peak sulfane sulfur levels in healthy or HF subjects at any dose (Figure [2](#cdr12128-fig-0002){ref-type="fig"}C,D). Pharmacokinetic curves following SG1002 treatment display a sustained elevation in sulfide levels in healthy patients (Figures [3](#cdr12128-fig-0003){ref-type="fig"} and [4](#cdr12128-fig-0004){ref-type="fig"}). Placebo H~2~S and sulfane sulfur pharmacokinetics are depicted in Table*** ***S1.

![Peak sulfide levels for healthy and heart failure subjects following 1st dose of 200, 400 and 800 mg SG1002 (individual maximum concentrations reached 0.5--4 h post administration). (**A**) Peak free H~2~S levels following 200, 400 and 800 mg BID in healthy subjects. (**B**) Peak free H~2~S levels following 200, 400 and 800 mg BID in heart failure subjects. (**C**) Peak sulfane sulfur levels following 200, 400 and 800 mg BID in healthy subjects. (**D**) Peak sulfane sulfur levels following 200, 400 and 800 mg BID in heart failure subjects. \**P* \< 0.05, \*\**P* \< 0.01 compared to baseline (pretreatment values) using a 1‐way ANOVA with a Bonferroni multiple comparison correction test. Values are expressed as mean ± SEM.](CDR-33-216-g002){#cdr12128-fig-0002}

![Pharmacokinetic analysis of free H~2~S and sulfane sulfur in healthy subjects. (**A**) Free H~2~S levels following 200 mg SG1002 BID, (**B**) 400 mg BID, and (**C**) 800 mg BID. (**D**) Free sulfane sulfur levels following 200 mg SG1002 BID, (**E**) 400 mg BID, and (**F**) 800 mg BID. Values are expressed as mean ± SEM. n = 5.](CDR-33-216-g003){#cdr12128-fig-0003}

![Pharmacokinetic analysis of free H~2~S and sulfane sulfur in heart failure subjects. (**A**) Free H~2~S levels following 200 mg SG1002 BID, (**B**) 400 mg BID, and (**C**) 800 mg BID. (**D**) Free sulfane sulfur levels following 200 mg SG1002 BID, (**E**) 400 mg BID, and (**F**) 800 mg BID. Values are expressed as mean ± SEM. n = 6.](CDR-33-216-g004){#cdr12128-fig-0004}

SG1002 Promotes Nitric Oxide Bioavailability in Healthy and Heart Failure Subjects {#cdr12128-sec-0016}
----------------------------------------------------------------------------------

Nitrite is an active storage form of NO and is an indicator of NO reserves and production. The prodrug, SG1002, promoted a sustained elevation in nitrite levels in healthy subjects compared to baseline values (Figure [5](#cdr12128-fig-0005){ref-type="fig"}A--C). In these subjects, peak nitrite levels were significantly increased following the 400 mg (2.0‐fold, *P* \< 0.05) and 800 mg (2.4‐fold, *P* \< 0.001) doses compared to pretreatment values (Figure [6](#cdr12128-fig-0006){ref-type="fig"}A). Similarly, peak nitrite levels in HF subjects following SG1002 therapy were elevated following 400 mg (*P* \< 0.05) and 800 mg (*P* \< 0.05) doses compared to baseline levels. Placebo nitrite pharmacokinetics are depicted in Table*** ***S1.

![Pharmacokinetic analysis of nitrite in healthy and heart failure subjects. (**A**) Nitrite levels following 200 mg SG1002 BID, (**B**) 400 mg BID, and (**C**) 800 mg BID in healthy subjects (n = 5). (**D**) Plasma nitrite levels following 200 mg SG1002 BID, (**E**) 400 mg BID, and (**F**) 800 mg BID in HF subjects (n = 6). Values are expressed as mean ± SEM.](CDR-33-216-g005){#cdr12128-fig-0005}

![Peak nitrite levels for healthy and heart failure subjects following 1st dose of 200, 400, and 800 mg SG1002 (individual maximum concentrations reached 0.5--4 h post administration). (**A**) Peak nitrite levels following 200, 400, and 800 mg BID in healthy subjects (n = 5). (**B**) Peak nitrite levels following 200, 400, and 800 mg BID in heart failure subjects (n = 6). \**P* \< 0.05, \*\*\**P* \< 0.001 compared to baseline (pretreatment values) using a 1‐way ANOVA with a Bonferroni multiple comparison correction test. Values are expressed as mean ± SEM.](CDR-33-216-g006){#cdr12128-fig-0006}

SG1002 Maintains BNP Levels in Heart Failure Patients {#cdr12128-sec-0017}
-----------------------------------------------------

Fold change in the stress responsive polypeptide, BNP, was calculated with paired correction to individual baseline levels. Circulating BNP concentrations were measure at baseline, day 7 (completion of 200 mg BID), day 14 (400 mg BID), and day 21 (800 mg BID). SG1002‐treated patients displayed steady BNP levels at all doses (Figure [7](#cdr12128-fig-0007){ref-type="fig"}A).

![Markers of cardiac health following SG1002 treatment in heart failure subjects. (**A**) Fold change in the stress responsive polypeptide, BNP. Circulating BNP concentrations were measure at baseline, day 7 (completion of 200 mg BID), day 14 (400 mg BID), and day 21 (800 mg BID). (**B**) Relative reduced (GSH) and oxidized (GSSG) glutathione levels in RBCs at baseline, after 7 days of 200 mg BID (day 7), after 7 days of 400 mg BID (day 14), and after 7 days of 800 mg BID (day 21). Values are expressed as mean ± SEM.](CDR-33-216-g007){#cdr12128-fig-0007}

SG1002 does not Alter Red Blood Cell Glutathione Content {#cdr12128-sec-0018}
--------------------------------------------------------

We measured the reduced (GSH) and oxidized (GSSG) glutathione levels in RBCs at baseline, after 7 days of 200 mg BID (day 7), after 7 days of 400 mg BID (day 14), and after 7 days of 800 mg BID (day 21). At these time points and dosages, we failed to observe any significant change in GSH, GSSH, or the GSH:GSSG ratio in either group (Figure [7](#cdr12128-fig-0007){ref-type="fig"}B).

Discussion {#cdr12128-sec-0019}
==========

Recent preclinical studies have shown that H~2~S attenuates adverse cardiac remodeling and dysfunction in the setting of HF [12](#cdr12128-bib-0012){ref-type="ref"}, [13](#cdr12128-bib-0013){ref-type="ref"}. These studies build upon previous findings that revealed the protective action of H~2~S against ischemic injury (myocardial [23](#cdr12128-bib-0023){ref-type="ref"}, hindlimb [24](#cdr12128-bib-0024){ref-type="ref"}, hepatic [9](#cdr12128-bib-0009){ref-type="ref"}, and stroke [25](#cdr12128-bib-0025){ref-type="ref"}), gastrointestinal damage [26](#cdr12128-bib-0026){ref-type="ref"}, atherosclerosis [27](#cdr12128-bib-0027){ref-type="ref"}, and metabolic syndrome [28](#cdr12128-bib-0028){ref-type="ref"}. The principal protective actions of H~2~S in these pathological states are as follows: potent antioxidant actions [29](#cdr12128-bib-0029){ref-type="ref"}, pro‐angiogenesic properties [30](#cdr12128-bib-0030){ref-type="ref"}, and preservation of mitochondrial function [23](#cdr12128-bib-0023){ref-type="ref"}, [25](#cdr12128-bib-0025){ref-type="ref"}. More recently, it has been reported that the administration of H~2~S restores redox balance and NO bioavailability via direct actions on eNOS to recouple this enzyme under pathological conditions [9](#cdr12128-bib-0009){ref-type="ref"}. This restoration of NO levels results in cytoprotective signal transduction resulting in tissue preservation [9](#cdr12128-bib-0009){ref-type="ref"}.

Novel, long‐acting, and controllable H~2~S‐based therapeutics (i.e., H~2~S donors, prodrugs, and H~2~S enzyme activators) may represent valuable candidates for drug development. Currently, H~2~S donors are very limited in scope for clinical development because of poor pharmacokinetics with a very short half‐life and uncontrolled release [6](#cdr12128-bib-0006){ref-type="ref"}. For example, commercially available inorganic salts, Na~2~S and NaHS, rapidly increase H~2~S concentration, but the increase in free‐H~2~S is very short lived (seconds) and these compounds have a very small therapeutic dose window leading to potential toxicity [31](#cdr12128-bib-0031){ref-type="ref"}. Use of these compounds for treating chronic disorders, such as HF, is not clinically feasible to supplement H~2~S levels in a sustained manner. Given the toxicity of supraphysiological H~2~S levels, it is critical that novel H~2~S agents with favorable pharmacokinetic profiles are developed for clinical application.

SG1002 is an α‐sulfur oral formulation H~2~S prodrug that has been examined in *in vivo*, preclinical studies of HF [12](#cdr12128-bib-0012){ref-type="ref"}. This study revealed cardioprotective actions including reductions in myocardial fibrosis and increased myocardial vascularity as well as significant increases in NO bioavailability. Results from preclinical studies demonstrating the effects of SG1002 on LV ejection fraction following transverse aortic constriction prompted us to test the safety and ability of SG1002 to provide sustained, nontoxic elevations in circulating H~2~S in man.

Overall, the present study demonstrated that SG1002 was well tolerated and safe in a small cohort of healthy volunteers and HF patients. There were no safety concerns at all doses in the healthy and HF subjects. The peak H~2~S levels did not exceed 0.7 *μ*M at any time point analyzed in the healthy subjects and reached a maximum of 1.1 *μ*M in one of the HF subjects. Even these levels remain within physiological range and remain below cytotoxic concentrations [32](#cdr12128-bib-0032){ref-type="ref"}. Free H~2~S plasma levels following SG1002 were elevated in the healthy subjects (Figure [2](#cdr12128-fig-0002){ref-type="fig"}) to a greater extent than increases observed in heart failure patients. It is likely that H~2~S derived from SG1002 was more rapidly degraded in HF patients as a result of increased oxidative stress associated with heart failure. Preclinical studies indicate that these levels would provide cardioprotection [12](#cdr12128-bib-0012){ref-type="ref"}. Due to the safety of the drug at the high dose, we believe that the 800 mg dose would be most appropriate in a phase II study. Similarly, nitrite levels rose to safe circulating levels. Although NO is a potent vasodilator (and H~2~S also exerts vasodilatory actions), the increases in NO and H~2~S bioavailability seen in both healthy and HF subjects did not accompany a drop in blood pressure. These findings are in accordance with other studies that show that long‐acting (i.e., extended release) NO donors (sodium nitrite) do not alter blood pressure when NO levels are kept within physiological levels [33](#cdr12128-bib-0033){ref-type="ref"}. Based on preclinical studies [3](#cdr12128-bib-0003){ref-type="ref"}, an increase in nitrite levels observed at the 800 mg dose would likely have physiological benefits in heart failure subjects.

Recent preclinical studies have shown that H~2~S increases the activity of eNOS and NO bioavailability [9](#cdr12128-bib-0009){ref-type="ref"}. Under homeostatic conditions, eNOS is a coupled homodimer that can be readily phosphorylated to either activate (ser1177) or inactivate (thr495) the enzyme [34](#cdr12128-bib-0034){ref-type="ref"}. Under pathological states, eNOS can uncouple to its monomeric form or undergo alterations in phosphorylation status of the enzyme, resulting in reduced NO levels [35](#cdr12128-bib-0035){ref-type="ref"}. Diminished levels of H~2~S due to genetic deficiency of CSE result in eNOS uncoupling and an inactive phosphorylation status [9](#cdr12128-bib-0009){ref-type="ref"}. In the present study, the H~2~S prodrug substantially augmented NO bioavailability that might be attributed to an increase in eNOS activity or a general decrease in systemic oxidative stress. Clinically, the direct effect of a therapeutic agent eNOS to increase NO bioavailability may be more advantageous than the transient burst of NO often associated with NO donors.

Increased oxidative stress results in cardiac contractile dysfunction and is one of the contributing factors in the transition from compensatory cardiac hypertrophy to decompensated HF [36](#cdr12128-bib-0036){ref-type="ref"}. H~2~S is known to reduce oxidative stress by direct inactivation of oxidant species and via upregulation of endogenous antioxidant defenses [29](#cdr12128-bib-0029){ref-type="ref"}, [37](#cdr12128-bib-0037){ref-type="ref"}. NO similarly promotes antioxidant enzyme defenses [38](#cdr12128-bib-0038){ref-type="ref"}. Finally, SG1002 may attenuate oxidative stress via a third mechanism by recoupling of eNOS. Uncoupled eNOS (as seen in HF) not only results in decreased NO generation, but leads to excessive peroxynitrite concentrations [39](#cdr12128-bib-0039){ref-type="ref"}. Peroxynitrite can interact with lipids, DNA, and proteins. These reactions elicit many downstream actions that can result in extensive oxidative injury, resulting in cellular necrosis and apoptosis [40](#cdr12128-bib-0040){ref-type="ref"}. We failed to observe a significant change in oxidative stress, as indicated by the concentration of the antioxidant glutathione in red blood cells. However, because this trial was primarily designed to examine safety, the sample size was not sufficient to rule out the antioxidant capacity of SG1002. A larger, phase II trial is required to examine whether SG1002 use in man will align with preclinical studies that more fully elucidate its capability of reducing free radical damage.

In summary, this trial revealed for the first time the safety of SG1002 in both healthy and HF patients. Furthermore, this novel H~2~S prodrug enhanced free H~2~S and H~2~S metabolites (sulfane sulfur) in humans. SG1002 significantly elevated NO bioavailability, as measured by plasma nitrite levels. The results from this trial are promising and indicate that the use of SG1002 to treat HF patients is worthy of further exploration. Currently, a larger, placebo‐controlled phase II study in HF patients is being designed to examine the ability of SG1002 to elevate H~2~S, reduce oxidative stress, and ultimately improve cardiac function.
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**Table S1.** Plasma H~2~S, sulfane sulfur, and nitrite pharmacokinetic data in placebo treated healthy and heart failure subjects.
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